BibTex format
@article{Cassir:2025:10.1016/j.cmi.2025.07.022,
author = {Cassir, N and Ghani, R and Biehl, LM and Graells, T and Kuijper, EJ and Mullish, BH and Marchesi, JR and Benech, N and on, behalf of The ESCMID Study Group for Host and Microbiota Interactions ESGHAMI},
doi = {10.1016/j.cmi.2025.07.022},
journal = {Clinical Microbiology and Infection},
title = {Non-antimicrobial therapies for recurrent urinary tract infection in women: is there a place for faecal microbiota transfer?},
url = {http://dx.doi.org/10.1016/j.cmi.2025.07.022},
year = {2025}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Background:Recurrent urinary tract infection (rUTI) is a common condition, affecting approximately one-third of women after an initial UTI. It significantly impacts health care costs and patients' quality of life. The relationship between the pathophysiology of UTI and the gut and vaginal microbiota is recognized as a contributing factor to rUTI in women. As antibiotic resistance among uropathogens continues to increase, there is a clear need to develop novel therapeutic interventions. Faecal microbiota transfer (FMT) is a potent nonantimicrobial strategy for modulating the gut microbiota; however, its clinical relevance in the context of rUTI is unclear.Objectives:This narrative review aimed to summarize the current evidence on the use of FMT for the treatment of rUTI, focusing on women, excluding those with mechanical dysfunctions such as urinary incontinence, neurogenic bladder, and bladder cancer, compared with other nonantimicrobial interventions. We also discussed the pathophysiology and epidemiology of rUTI to identify patients for whom microbiota-targeting therapies may be the most effective.Content:Periurethral colonization and migration to the bladder of uropathogens that inhabit the gut and vagina have been linked to the aetiology of UTI in women, particularly in patients with multidrug-resistant organisms. FMT appears to be a promising approach for preventing the clinical development of rUTI, although prospective data remain limited. In contrast, other reported nonantimicrobial strategies targeting the gut and urogenital microbiota have shown variable significant clinical efficacy. Prospective randomized controlled clinical trials are then needed to further confirm a potential therapeutic benefit, optimize the FMT procedure, and better assess its cost-effectiveness.
AU - Cassir,N
AU - Ghani,R
AU - Biehl,LM
AU - Graells,T
AU - Kuijper,EJ
AU - Mullish,BH
AU - Marchesi,JR
AU - Benech,N
AU - on,behalf of The ESCMID Study Group for Host and Microbiota Interactions ESGHAMI
DO - 10.1016/j.cmi.2025.07.022
PY - 2025///
SN - 1198-743X
TI - Non-antimicrobial therapies for recurrent urinary tract infection in women: is there a place for faecal microbiota transfer?
T2 - Clinical Microbiology and Infection
UR - http://dx.doi.org/10.1016/j.cmi.2025.07.022
ER -